Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Blogs > Drug > Biosimilar Boon for Europe’s Payers as Humira Price Falls

Biosimilar Boon for Europe’s Payers as Humira Price Falls

November 18, 2018 | Drug

Melanie senior

AbbVie is being hit harder than expected by the October 2018 arrival in Europe of biosimilar versions of Humira (adalimumab). Europe’s payers were better prepared than ever to take full advantage of the competition, helping push the price of this top-selling drug down by 80% in some markets. With at least four copies already launched and more to follow, AbbVie leadership was forced to concede, during an early November investor call, that they had under-estimated European sales erosion. Current estimates are now a 26-27% drop-off in 2019, resulting from more aggressive discounts. Just how aggressive isn’t clear. In a call with Credit Suisse analysts in early November 2018, AbbVie management was tight-lipped on whether it had gone to 80% or not, or which countries –if any- it has walked away from. Still, CS lowered their target price for AbbVie shares, underscoring the extent of the risk to the company.

The adalimumab launches show that Europe’s biosimilars market has come of age. The challenge for biosimilar companies is no longer primarily to educate physicians and payers about what biosimilars are; it is now about differentiating their own version from the competitors, and trying to ensure price falls do not become unsustainable.

Adalimumab caught the headlines because of its size. But it won’t be the last biosimilar: Europe’s payers are already lining up to take advantage of copies of Amgen’s neutropenia drug Neulasta (pegfilgrastim), three of which have already received European Medicines Agency approval. If the uptake of biosimilar filgrastim (Neupogen) is anything to go by, 2019 could be a painful year for Neulasta sales – though Amgevita, Amgen’s biosimilar adalimumab, may help compensate. Amgevita was the first of the Humira copycats to be approved and among the first to launch on October 16, 2018.

Europe’s payers are united in their hunger for savings, but each differs in the measures and tools used to drive uptake. Some countries run nation-wide, single winner tenders where price is everything. Others prefer multi-winner tenders, taking into account local provider preferences for factors such as product presentation, stability/shelf-life, and consistency of supply. Biosimilars Market Access in the EU, a Datamonitor report, outlines country-by-country biosimilar dynamics, including data on the penetration of approved biosimilars in individual markets. The report explains the many variables that influence biosimilar success across Europe, providing recommendations on how to address regulatory, legal and commercial challenges in each region. It also provides background on naming and labelling issues across Europe, and explains Europe’s evolving intellectual property landscape and the IP issues associated with the class.

Understanding the national and regional nuances across Europe’s biosimilar markets is critical to commercial success in biosimilars, as the category matures and as competition heats up. Future launches are likely to be faster, with more aggressive price-cuts.

Over a decade since the launch of Europe’s first biosimilar, Sandoz’s Omnitrope (somatropin), Europe’s payers and patients now have experience across a range of biosimilars, from relatively simple molecules like growth hormone or erythropoietin to the more complex monoclonal antibodies like infliximab or adalimumab.

And as real-world data accumulates around biosimilar use and switching across different therapy areas, the full impact of this category is becoming clearer. Biosimilars are not simply forcing down prices. They are also beginning to influence treatment pathways in some markets, as providers begin to use more widely-available biologics earlier than payer budgets would previously allow.

This is a category to watch.

Related Products

Biosimilars Market Access in the EU
Biosimilars Market Access in Psoriatic Arthritis
As Humira Biosimilars Arrive, Battle Lines Shift From Education To Sustainability

FacebookTweetPin

Related posts:

From Herceptin to Rozlytrek: how cancer drugs are getting more personalized
Drug

From Herceptin to Rozlytrek: how cancer drugs are getting more personalized

  • September, 25 2019
  • 2501

In August 2019, the US FDA approved Roche’s Rozlytrek (entrectinib) for cancer patients whose solid tumors harbor a particular genetic mutation called NTRK. The approval comes more than 20 years after the very first ‘targeted’ breast cancer therapy reache

As Rare Disease Drugs Multiply, So Must Creative Ways to Pay for Them
Drug

As Rare Disease Drugs Multiply, So Must Creative Ways to Pay for Them

  • February, 19 2019
  • 1373

Patients suffering from one of the many hundreds of rare diseases known to exist have a better chance than ever of finding a treatment. Companies large and small continue to invest, given high unmet need and very targeted populations. Progress must contin

Gene therapy ‘cures’ force new payment models
Drug

Gene therapy ‘cures’ force new payment models

  • December, 28 2018
  • 1230

Solving the scientific challenges around gene therapy took decades. Figuring out how to pay for these new medicines will, hopefully, be quicker. As gene- and cell-therapies begin to trickle onto the market, with pipelines expanding behind, payers and manu

Related Content
Read more
lorem
Biosimilars Battlegrounds

  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.
Biopharma companies have the cash and are ready to deal Orphan Assets Still Hot as Pricing Debate Rages

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top